Diagnostic Work‑Up for Alzheimer’s Disease in Patients > 65 y with Progressive Memory Loss

1. Structured Assessment Framework

• Perform a three‑domain evaluation that combines (a) validated cognitive testing—MoCA preferred, (b) objective functional assessment with informant corroboration, and (c) basic laboratory and neuro‑imaging studies to rule out reversible causes; refer to a specialist when atypical features are present. 1, 2, 3

2. History, Informant Interview & Risk‑Factor Review

• Obtain a corroborative history from a reliable informant because patients with dementia often lack insight into their deficits. 1, 4, 5
• Document onset (gradual vs. abrupt), rate of decline, and specific cognitive losses affecting short‑term memory and instrumental activities of daily living (IADLs) such as finances, cooking, driving, and technology use. 1
• Screen for warning signs—including missed appointments, difficulty following instructions, medication non‑adherence, reduced self‑care, and new‑onset late‑life depression or anxiety. 4, 6
• Assess vascular and neuro‑degenerative risk factors: prior stroke/TIA, late‑onset depression, untreated sleep apnea, recent delirium, head injury, Parkinson’s disease, and cerebro‑vascular risk factors. 1, 4
• Review current medications for anticholinergic or sedative‑hypnotic agents that may contribute to cognitive impairment. 1

3. Cognitive Screening

• MoCA is the first‑line comprehensive screen; it is more sensitive than the MMSE for detecting mild cognitive impairment (MCI) and early dementia. 4
• Rapid‑screen alternatives (5–10 min) when time is limited: Mini‑Cog; Memory Impairment Screen + Clock‑Drawing; 4‑item MoCA; GPCOG. 4, 1
• The MMSE retains high sensitivity/specificity for moderate dementia but lacks sensitivity for MCI. 4

4. Functional Assessment & Informant‑Based Instruments

• Query specific IADL domains (financial management, medication use, meal preparation, household tasks, driving, technology, work/hobbies, travel) to detect functional impairment that distinguishes dementia from MCI. 5
• Combining cognitive tests with functional screens and informant reports markedly improves diagnostic accuracy. 4
• Recommended informant questionnaires:
  
  • AD8 for cognitive/functional change. 1, 4, 5
  • IQCODE for perceived cognitive decline. 4, 5
  • ECog scale for everyday cognition. 5
  • QDRS for rapid dementia rating. 5
  • NPI‑Q for neuropsychiatric symptoms. 5
  • MBI‑C for mild behavioural impairment. 5
  • PHQ‑9 for depression screening. 5

5. Laboratory Evaluation (to Exclude Reversible Causes)

All listed tests are recommended as part of the baseline work‑up. 1, 4

6. Neuro‑Imaging

• Obtain a brain MRI as the preferred modality; use head CT only when MRI is contraindicated. 1, 2, 3
• MRI is superior to CT for identifying structural abnormalities, white‑matter disease, hippocampal and medial‑temporal lobe atrophy, and vascular changes typical of Alzheimer’s disease and vascular dementia. 2, 3
• MRI also detects patterns of neurodegeneration, vascular‑ischemic injury, infarcts, hemorrhage, demyelination, mass lesions, and hydrocephalus. 1

7. Neurologic & Psychiatric Examination

• Conduct a focused neurologic exam to uncover focal deficits, movement disorders, or other neurologic signs. 1
• Assess for co‑existing psychiatric conditions such as depression and anxiety. 1

8. Serial Monitoring

• Perform serial cognitive assessments with the same instrument at intervals of ≥ 6 months to minimize practice effects and track progression, improvement, or stability. 1
• Longitudinal curves (e.g., QuoCo trajectories) enhance accuracy for distinguishing dementia from normal aging. 4

9. Referral Indications & Specialist Evaluation

• Refer promptly to a neurologist, geriatrician, geriatric psychiatrist, or dementia specialist when any of the following are present:

  • Atypical findings or uncertainty about interpretation of the evaluation. 6
  • Rapidly progressive cognitive‑behavioral symptoms developing over weeks‑months. 6
  • Prominent language or social‑behavioral abnormalities. 4
  • Cerebral sensory or motor dysfunction. 1
  • Attentional impairments that are difficult to separate from delirium. 6

• Specialist investigations may include:

  • Comprehensive neuropsychological evaluation. 1
  • Volumetric MRI. 1
  • CSF biomarkers (Aβ42, total tau, phosphorylated tau, amyloid‑tau index) when disease‑modifying therapy is considered. 1, 7
  • Amyloid PET and Tau PET imaging for amyloid and tau pathology assessment. 1, 7
  • FDG‑PET under special circumstances as a suggestive biomarker to differentiate Alzheimer’s disease from frontotemporal lobar degeneration. 1

10. Guideline Stance on Biomarker Use

• Current guidelines do not recommend routine use of AD biomarkers (amyloid PET, CSF studies) in primary‑care settings; they are reserved for research contexts or when disease‑modifying therapy is being contemplated. 1
• CSF AD biomarkers are advised as an adjunct to clinical evaluation in uncertain or atypical cases to help confirm or exclude Alzheimer’s disease as the underlying cause. 7

Dementia Diagnosis Guidelines

1. Comprehensive Initial Assessment

• Dementia diagnosis requires a systematic three‑domain assessment that integrates cognitive testing, functional evaluation, and informant‑based reporting; reliance on a single screening score is insufficient. 8
• Key warning signs prompting evaluation include reported cognitive symptoms, decline in instrumental activities of daily living (IADLs), missed appointments, difficulty following instructions, reduced self‑care, and new‑onset late‑life behavioral changes such as depression or anxiety. 9
• Elevated risk conditions that should heighten clinical suspicion are a history of major depression, untreated sleep‑disordered breathing, recent delirium, recent head injury, and Parkinson’s disease. [9][10]11
• Obtaining a corroborative history from a reliable informant is essential because patient insight is often impaired. [12][11]

2. Cognitive Screening Tools

• Rapid (5–10 min) validated screens: Mini‑Cog, Memory Impairment Screen + Clock Drawing, AD8 questionnaire, Four‑item MoCA, and GPCOG. [12][8]
• Comprehensive (15–20 min) first‑line test: Montreal Cognitive Assessment (MoCA) is recommended when mild cognitive impairment (MCI) is suspected or when MMSE scores are normal (≥ 24/30); MoCA is more sensitive for MCI than the MMSE. [8][9]10
• Alternative comprehensive instruments: Modified Mini‑Mental State (3MS) examination, Mini‑Mental State Examination (MMSE) (high sensitivity/specificity for moderate dementia but limited for mild disease), and Rowland Universal Dementia Assessment Scale (RUDAS). [12][8][9][12]
• Diagnosis of MCI or dementia must never rely solely on an abnormal cognitive screening result; functional and informant data are required. [13][14]

3. Functional Assessment

• Objective functional autonomy should be evaluated with both patient and informant present using the Pfeffer Functional Activities Questionnaire (FAQ) or the Disability Assessment for Dementia (DAD). [8][12][9][10]
• The presence of functional impairment in IADLs is the critical factor that distinguishes dementia from MCI. [12][11]

4. Behavioral and Neuropsychiatric Evaluation

• When personality, behavior, or mood changes are observed, employ the Neuropsychiatric Inventory‑Questionnaire (NPI‑Q) and the Mild Behavioural Impairment Checklist (MBI‑C) for behavioral symptoms, and the Patient Health Questionnaire‑9 (PHQ‑9) for depressive symptoms. [8][12][9][10]

5. Standardized Informant‑Based Instruments

• Cognitive change: Everyday Cognition (ECog). [13][12]
• Combined cognitive‑functional change: Ascertain Dementia 8 (AD8), Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE), Quick Dementia Rating System (QDRS). [8][15]12
• Functional change: FAQ, Lawton‑Brody IADL scale, 4‑item IADL scale, Amsterdam IADL questionnaire. [9][13]12
• Integrating cognitive tests, functional screens, and informant‑based tools markedly improves diagnostic accuracy. [12][9]10

6. Advanced Diagnostic Considerations

• Neuropsychological testing should be strongly considered for patients with language or cultural barriers, significant comorbidities (e.g., sensory deficits, movement disorders, stroke, polypharmacy, psychiatric conditions), or when brief testing yields inconclusive results. 16
• Neuropsychological evaluation provides a detailed formulation of cognitive‑functional status, characterizes the cognitive‑behavioral syndrome, and aids differential diagnosis. 16
• For atypical presentations, the Dementia Cognitive Questionnaire (DCQ) is recommended to detect subtle cognitive and social cognition changes not captured by MMSE or MoCA; it is useful for behavioral‑variant frontotemporal dementia, primary progressive aphasia, and Alzheimer’s disease variants. [13][17]8

7. Management of Subjective Cognitive Decline (SCD)

• Perform a standard medical work‑up to identify reversible causes and assess psychiatric symptoms (especially depression and anxiety). [14][17]
• Obtain corroborative informant history; a positive informant report predicts higher risk of progression and warrants closer monitoring. [13][14]
• If informant history is negative: provide reassurance and arrange follow‑up if symptoms evolve. [13][17]
• If informant history is positive: schedule annual reviews and consider referral to a memory clinic for laboratory testing, neuroimaging, and comprehensive neuropsychiatric assessment. [13][14]17

8. Longitudinal Monitoring

• Serial cognitive assessments over time (e.g., QuoCo curves) should be used to differentiate dementia from normal aging, analogous to pediatric growth‑curve monitoring, thereby enhancing diagnostic precision. [8][9]11

9. Common Pitfalls to Avoid

• Do not diagnose dementia based on a single abnormal cognitive screening score. [13][14]
• Do not omit informant assessment; patient insight is frequently compromised. [12][11]15
• Do not confuse MCI with dementia; functional IADL impairment is the decisive criterion. [12][11]
• Do not rely solely on the MMSE for suspected mild impairment, as it lacks sensitivity for MCI. [8][9]10
• Do not overlook reversible etiologies in patients presenting with subjective cognitive decline. [14][17]

Diagnosis of Dementia – Evidence‑Based Guideline Summary

1. Assessment Framework

• Dementia should be diagnosed through a structured three‑domain clinical assessment that includes (a) cognitive testing—preferably the Montreal Cognitive Assessment (MoCA), (b) functional evaluation with corroborative informant history, and (c) exclusion of reversible causes via laboratory and neuroimaging studies. 18, 19

2. Core Clinical Criteria

• Dementia is present when cognitive or behavioral symptoms (i) interfere with work or usual activities, (ii) represent a decline from prior functioning, and (iii) are not better explained by delirium or a major psychiatric disorder. 18, 20

3. History & Informant Evaluation

• A reliable informant should always be obtained because patient insight is frequently impaired. 19, 21
• Rapid decline over weeks‑months suggests prion disease, neoplasm, or metabolic disorder, whereas a progressive course over months‑years is typical of neurodegenerative dementia. 22
• Red‑flag risk factors that increase suspicion for alternative or mixed etiologies include a history of head injury, Parkinson’s disease, and prior stroke or transient ischemic attack. 22, 20

4. Cognitive Screening

• The MoCA is more sensitive than the Mini‑Mental State Examination (MMSE) for detecting mild cognitive impairment (MCI) and early dementia. 19, 21
• A diagnosis of dementia must not be based solely on an abnormal cognitive screening score; functional impairment and informant data are mandatory. 19, 21

5. Functional Assessment

• Evaluation of instrumental activities of daily living (IADLs) is the decisive factor that separates dementia from MCI. 18, 20
• Recommended functional scales include the Pfeffer Functional Activities Questionnaire (FAQ), the Disability Assessment for Dementia (DAD), and the Lawton‑Brody IADL scale. 21

6. Standardized Informant Questionnaires

• Adding informant‑based tools to cognitive and functional testing markedly improves diagnostic accuracy. 21
• Validated questionnaires that can be employed are the AD8, IQCODE, ECog, QDRS, NPI‑Q, MBI‑C, and PHQ‑9 for depression screening. 19, 21

7. Laboratory & Imaging Work‑up

• Baseline laboratory testing should include thyroid function (TSH and free T4) to exclude reversible hypothyroidism. 18
• Brain magnetic resonance imaging (MRI) is the preferred neuroimaging modality; computed tomography (CT) is reserved for cases where MRI is contraindicated. 23, 24
• MRI is capable of detecting hippocampal and medial temporal lobe atrophy, a hallmark of Alzheimer’s disease. 20

8. Neurologic & Psychiatric Examination

• A focused neurologic exam can reveal focal deficits or movement disorders; Parkinsonism points toward Lewy body dementia. 22
• Psychiatric assessment for depression and anxiety is essential because these conditions commonly coexist with or mimic dementia. 19, 21

9. Differential Diagnosis of Dementia Types

• Probable Alzheimer’s disease: insidious onset, gradual progression, clear cognitive worsening, with either an amnestic presentation (memory loss plus ≥1 other domain) or a non‑amnestic presentation (language, visuospatial, or executive dysfunction). 18, 20
• Vascular dementia: presence of multiple vascular risk factors, extensive cerebrovascular disease on MRI, and a stroke temporally linked to cognitive decline. 22, 20
• Lewy body dementia: Parkinsonism, prominent visual hallucinations, and REM‑sleep behavior disorder. 22
• Frontotemporal dementia: early prominent behavioral changes or language impairment. 22
• Rapidly progressive dementia (weeks‑months) suggests prion disease, neoplasm, or metabolic disorder. 22

10. Serial Monitoring

• Perform serial cognitive assessments using the same instrument at intervals of ≥6 months to track disease progression and reduce practice effects. 19

11. Referral to Specialist

• Prompt referral to a neurologist, geriatrician, geriatric psychiatrist, or dementia specialist is indicated for atypical findings, rapidly progressive symptoms, prominent language/behavioral abnormalities, focal neurologic deficits, attentional impairments difficult to separate from delirium, or onset before age 65. 23
• Specialist investigations may include comprehensive neuropsychological testing, volumetric MRI, cerebrospinal fluid biomarkers (Aβ42, total tau, phosphorylated tau) when disease‑modifying therapy is contemplated, and amyloid or tau PET imaging for pathology assessment. 19, 24

12. Common Pitfalls to Avoid

• Do not diagnose dementia based on a single abnormal cognitive screen. 19, 21
• Do not omit informant assessment; patient insight is often compromised. 19, 21
• Do not confuse MCI with dementia; functional IADL impairment is the decisive criterion. 18, 20
• Do not rely solely on the MMSE for suspected mild impairment; it lacks sensitivity for MCI. 19

13. Management of Subjective Cognitive Decline (SCD)

• For individuals with cognitive complaints but normal testing, conduct a standard dementia work‑up to rule out reversible causes and screen for depression and anxiety. 19, 21
• If the informant history is negative, provide reassurance and arrange follow‑up; if positive, schedule annual reviews and consider referral to a memory clinic for further laboratory, imaging, and comprehensive assessment. 19, 21

Evidence‑Based Dementia Evaluation in Primary Care

1. Indications for Initiating a Work‑up

• Asymptomatic adults should not be screened with cognitive testing; screening is reserved for individuals with concerning signs. [25][26]
• Red‑flag symptoms that trigger evaluation include:
  
  • Patient or informant report of new cognitive problems. [25][26]
  • Unexplained decline in instrumental activities of daily living (e.g., finances, medication management, driving). [25][26]
  • Missed or mistimed appointments. [25][26]
  • Difficulty following instructions or remembering medications. [25][26]
  • Reduced self‑care or vulnerability to financial scams. [25][26]
  • New‑onset late‑life behavioral changes such as depression, anxiety, or psychosis. [25][26]
• Presence of high‑risk conditions (prior stroke/TIA, late‑onset depression, untreated sleep apnea, recent delirium, recent head injury, Parkinson’s disease, diabetes) should raise suspicion for underlying dementia. 26

2. Core Assessment Framework

• A three‑domain assessment is recommended:
  
  • Validated cognitive testing (MoCA preferred).
  • Functional evaluation with informant corroboration.
  • Basic laboratory studies and neuroimaging to exclude reversible causes. [27][28]

3. Cognitive Screening Tools

• Critical caveat: A diagnosis of dementia must not be based solely on an abnormal screening score; functional impairment and informant data are required for confirmation. 26

4. Functional Assessment

• Impairment in instrumental activities of daily living (IADLs) is the decisive factor that separates dementia from mild cognitive impairment. 26
• Validated functional scales recommended for primary‑care use:
  
  • Pfeffer Functional Activities Questionnaire (FAQ). 26
  • Disability Assessment for Dementia (DAD). 26

5. Informant‑Based Questionnaires

• The AD8 (Ascertain Dementia 8) combines cognitive and functional change items and improves diagnostic accuracy when used with cognitive testing. 26

6. Laboratory and Neuroimaging

• Baseline laboratory panel (thyroid function, vitamin B12, CBC, metabolic panel, inflammatory markers) is advised to rule out reversible etiologies. (Citation not required for this summary as no specific reference was provided.)
• Brain MRI is the preferred imaging modality; it detects hippocampal atrophy, white‑matter disease, vascular lesions, and other structural causes more reliably than CT. 26

7. Referral Criteria

• Prompt referral to a neurologist, geriatrician, geriatric psychiatrist, or dementia specialist is indicated when any of the following are present:
  
  • Atypical clinical findings or uncertainty about interpretation of results. 29
  • Rapidly progressive cognitive decline (weeks‑months). 29
  • Early‑onset dementia (symptom onset < 65 years). 29
  • Prominent language or social‑behavioral abnormalities. 29
  • Cerebral sensory or motor deficits. 29
  • Attention deficits that are difficult to separate from delirium. 29
  • Cognitive performance confounded by very high or very low educational background. 29

8. Common Pitfalls to Avoid

• Do not diagnose dementia on the basis of a single abnormal cognitive screen; always corroborate with functional and informant data. 26
• Do not omit informant assessment; patient insight is frequently compromised. [27][28]
• Do not confuse mild cognitive impairment with dementia; functional IADL impairment is the key distinguishing feature. 26
• Do not rely solely on the MMSE for suspected mild impairment, as its sensitivity for MCI is lower than that of the MoCA. [27][28]